Stock AMGN34 AMGEN INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Amgen Inc. Sao Paulo

Equities

AMGN34

BRAMGNBDR004

Market Closed - Sao Paulo
Other stock markets
 15:18:13 2024-06-19 EDT 		5-day change 1st Jan Change
58.56 BRL +18.33% Intraday chart for Amgen Inc. +0.43% +17.24%
06-14 Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto DJ
06-14 Amgen Says FDA Approves Blincyto to Treat Type of Blood Cancer MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Amgen Inc. Announces U.S. Food and Drug Administration Approves Blincyto
Sector Update: Health Care Stocks Softer Friday Afternoon
Wall Street finit contrastée, nouveaux records pour Nasdaq et S&P 500
Race Oncology Validates Efficacy of Blood Cancer Therapy in Animal Study; Shares Rise 6%
AbbVie's tight grip on Humira market raises concerns about biosimilars
Amgen Says Phase 3 Trial of Potential Autoimmune Disease Treatment Meets Endpoints
Amgen's drug meets main goal in late-stage study for rare disease
Amgen Announces Positive Results for Phase 3 Registrational Trial Evaluating Uplizna® (Inebilizumab-Cdon) for Treatment of Immunoglobulin G4-Related Disease (Igg4-Rd)
Amgen Inc. Appoints Dr. Mary E. Klotman as Director
US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment
Previsiones de venta de medicamentos para adelgazar suben a 150.000 millones de dólares
Weight-loss drug forecasts jump to $150 billion as supply grows
Sandoz : AMM pour Wyost et Jubbonti dans l'UE
Un test de Roche reçoit la désignation de dispositif révolutionnaire aux USA
Sandoz: feu vert de la Commission européenne pour Wyost et Jubbonti
Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test
Roche erhält von FDA "Breakthrough Device Designation" für Bluttest
Amgen and AstraZeneca's Lung Disease Drug Study Reports Mixed Results
Amgen Announces the Results of the Phase 2a COURSE Trial Evaluating Tezspire® (Tezepelumab-Ekko) in People with Moderate to Very Severe Chronic Obstructive Pulmonary Disease
FDA Approves Amgen's IMDELLTRA?? (Tarlatamab-Llle) for the Treatment of Adult Patients with Extensive-Stage Small Cell Lung Cancer
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AMGN Stock
  4. AMGN34 Stock
  5. News Amgen Inc.
  6. Other languages